Folic acid to prevent neural tube defects: A potential pharmacy initiative with public health implications

Hospital Pharmacy

Volumn 39, Issue 10, 2004, Pages 962-969

  Ryan, Melody ^a  

^a University of Kentucky   (United States)

Author keywords

Folic acid; Neural tube defects

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYANOCOBALAMIN; ETHOSUXIMIDE; FOLIC ACID; FOLIC ACID ANTAGONIST; HOMOCYSTEINE; METHIONINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ANENCEPHALUS; DIABETES MELLITUS; DIET SUPPLEMENTATION; EDUCATION; EPILEPSY; ETHNOLOGY; FOLIC ACID BLOOD LEVEL; FOLIC ACID DEFICIENCY; HEALTH CARE PERSONNEL; HUMAN; HYPERINSULINEMIA; MATERNAL CARE; MEDLINE; MENINGOMYELOCELE; NEURAL TUBE DEFECT; OBESITY; OCCUPATION; PATIENT EDUCATION; PHARMACIST; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY DISORDER; PUBLIC HEALTH; RECURRENT DISEASE; REVIEW; RISK FACTOR; SOCIAL STATUS; SPINA BIFIDA;

EID: 5444230594     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1177/001857870403901007     Document Type: Review

References (49)

1. Sarnat HB, Flores L. Developmental disorders of the nervous system. In: Bradley WG, Daroff RB, Fenichel GM, Marsden CD, Eds. Neurology in Clinical Practice, Boston, MA: Butterworth Heinemann; 2000, 1561-83.
2. Muller T, Arbeiter K, Aufricht C. Renal function in meningomyelocele: Risk factors, chronic renal failure, renal replacement therapy and transplantation. Curr Opin Urol. 2002;12:479-84.
3. Czeizel AE, Toth M, Rockenbauer M. Population-based case control study of folk acid supplementation during pregnancy. Teratology. 1996;53:345-51.
4. Canfield MA, Annegers JF, Brender JD, et al. Hispanic origin and neural tube defects in Houston/Harris County, Texas. II, Risk factors. Am J Epidemiol. 1996;143:12-24.
5. Kirby R, Petrini J, Alter C, and The Hispanic Ethnicity Birth Defects Workgroup. Collecting and interpreting birth defects surveillance data by Hispanic ethnicity: A comparative study. Teratology. 2000; 61:21-7.
6. Feuchtbaum LB, Currier RJ, Riggle S, et al. Neural tube defect prevalence in California (1990-1994): Eliciting patterns by type of defect and maternal race/ethnicity. Genet Test. 1999;3:265-72.
7. Blatter BM, Roeleveld N, Zielhuis GA, et al. Spina bifida and parental occupation. Epidemiology. 1996;7:188-93.
8. Shaw GM, Nelson V, Olshan AF. Paternal occupational group and risk of offspring with neural tube defects. Paediatr Perinat Epidemiol. 2002;16:328-33.
9. Wasserman CR, Shaw GM, Selvin S, et al. Socioeconomic status, neighborhood social conditions, and neural tube defects. Am J Public Health. 1998;88:1674-80.
10. Waller DK, Mills JL, Simpson JL, et al. Are obese women at higher risk for producing malformed offspring? Am J Obstet Gynecol. 1994;170:541-8.
11. Shaw GM, Velie EM, Schaffer D. Risk of neural tube defect-affected pregnancies among obese women. J Am Med Assoc. 1996;275:1093-6.
12. Werler MM, Louik C, Mitchell AA, et al. Prepregnant weight in relation to risk of neural tube defects. J Am Med Assoc. 1996;275:1089-92.
13. Hendricks KA, Nuno OM, Suarez L, et al. Effects of hyperinsulinemia and obestiy on risk of neural tube defects among Mexican Americans. Epidemiology. 2001;12:630-5.
14. Becerra JE, Khoury MJ, Cordero JF, et al. Diabetes mellitus during pregnancy and the risks for specific birth defects: A population-based case-control study. Pediatrics, 1990;85:1-9.
15. Hinks LJ, Ogilvy-Stuart A, Hambidge KM, et al. Maternal zinc and selenium status in pregnancies with a neural tube defect or elevated plasma alphafetoprotein. BrJ Obstet Gynaecol. 1989;96: 61-6.
16. Hibbard ED, Smithells RW, Folic acid metabolism and human embryopathy. Lancet. 1965;1:1254-5.
17. 12 in relation to neural tube defects. Br J Obstet Gynaecol. 1996;103:319-24.
18. Schwaninger M, Ringleb P, Winter R, et al. Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. Epilepsia. 1999;40:345-50.
19. 12 in reduction of risk of vascular disease. Lancet. 2002;359:227-8.
20. Hernandez-Diaz S, Werler MM, Walker AM, et al. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol. 2001;153:961-8.
21. Samren EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: A joint European prospective study of human teratogenesis associated with maternal epilepsy, Epilepsia. 1997;38:981-90.
22. Shaw GM, Schaffer D, Velie EM, et al. Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects. Epidemiology. 1995;6:219-26.
23. Mulinare J, Cordero JF, Erickson JD, et al. Periconceptional use of multivitamins and the occurrence of neural tube defects. J Am Med Assoc. 1988;260:3141-5.2.
24. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med. 1992;327:1832-5.
25. Smithells RW, Nevin NC, Seller MJ, et al. Further experience of vitamin supplementation for prevention of neural tube defect recurrences. Lancet. 1983;1:1027-31.
26. Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study, MRC Vitamin Study Research Group. Lancet. 1991;338:131-7.
27. 12, Pantothenic Acid, Biotin, and Choline. Institute of Medicine; 2000.
28. 28.American Academy of Pediatrics, Committee on Genetics. Folic acid for the prevention of neural tube defects. Pediatrics. 1999;104(2 pt 1):325-27.
29. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Recomm Rep. 1992;41(RR-14):1-7.
30. 30.ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Obstet Gynecol. 2003;102:203-13.
31. Practice parameter: Management issues for women with epilepsy (summary statement): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 1998;51:944-8.
32. Nulman I, Laslo D, Koren G. Treatment of epilepsy in pregnancy. Drugs. 1999;57:535-44.
33. Tettenborn B, Genton P, Polson D. Epilepsy and women's issues: An update. Epileptic Disord. 2002;4(suppl 2):S23-31.
34. Knowledge and use of folic acid by women of childbearing age - United States, 1995 and 1998. MMWR Morb Mortal Wkly Rep. 1999;48:325-7.
35. Jacques PF, Felson DT, Tucker KL, et al. Plasma 25-hydroxyvitamin D and its determinants in an elderly population sample. Am J Clin Nutr. 1997;66:929-36.
36. Oakley G, Wild N, Omenn G. Provide the citizens of New Zealand the miracle of folic acid fortification. N Z Med J. 2003;116:U302.
37. Tucker KL, Mahnken B, Wilson PW, et al. Folic acid fortification of the food supply: Potential benefits and risks for the elderly population. J Am Med Assoc. 1996;276:1879-85.
38. Folic Acid campaign and evaluation - Southwestern Virginia, 1997-1999. MMWR Morb Mortal Wkly Rep. 1999;48:914-7.
39. de la Vega A, Salicrup E, Verdiales M. A nationwide program for the use of preconceptional folic acid to prevent the development of open neural tube defects. Who is really using folic acid? P R Health Sci J. 2002;21:7-9.
40. Mayer JA, Eckhardt L, Stepanski BM, et al. Promoting skin cancer prevention counseling by pharmacists. Am J Public Health. 1998;88:1096-9.
41. Giles JT, Kennedy DT, Dunn EC, et al. Results of a community pharmacy-based breast cancer risk-assessment and education program. Pharmacotherapy. 2001;21:243-53.
42. Bower C, Blum L, O'Daly K, Higgins C, et al. Promotion of folate for the prevention of neural tube defects: Knowledge and use of periconceptional folic acid supplements in Western Australia, 1992 to 1995. Aust N Z J Public Health. 1997;21:716-21.
43. Lynch SM. Assessment of student pharmacists' knowledge concerning folic acid and prevention of birth defects demonstrates a need for further education. J Nutr. 2002;132:439-42.
44. De Jong-van den Berg LTW, van der Zee AH, Schaafsma E, et al. Counselling women about periconceptional use of folic acid: the role of the community pharmacist can be improved. Int J Pharm Pract. 1999;7:138-42.
45. Anderson C, Rajyaguru R. The role of community pharmacists and medicines counter assistants in health promotion: reflections from a folic acid campaign. Int J Pharm Pract. 2002;3:17-22.
46. Egen V, Hasford J. Prevention of neural tube defects: Effect of an intervention aimed at implementing the official recommendations. Soz Praventivmed. 2003;48:24-32.
47. US Food and Drug Administration. Folic acid fortification. US Food and Drug Administration; February 29, 1996.
48. Ray JG, Meier C, Vermeulen MJ, Boss S, et al. Association of neural tube defects and folic acid food fortification in Canada. Lancet. 2002;360:2047-8.
49. Felkner M, Suarez L, Hendricks K, Gunter EW. Blood folate levels on the Texas-Mexico border. Tex Med. 2002;98:58-60.